<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1305257381
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zylinamet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LINAGLIPTIN,METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5,1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        142.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Alrai Pharmaceutical industry Co. (L.L.C)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your tablet is Zylinamet. It contains two different active substances linagliptin and metformin.</p><p>&bull; Linagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors).</p><p>&bull; Metformin belongs to a class of medicines called biguanides.</p><p><strong>How Zylinamet works </strong></p><p>The two active substances work together to control blood sugar levels in adult patients with a form of diabetes called &lsquo;type 2 diabetes mellitus&rsquo;. Along with diet and exercise, this medicine helps to improve the levels and effects of insulin after a meal and lowers the amount of sugar made by your body.</p><p>This medicine can be used alone or with certain other medicines for diabetes like sulphonylureas, empagliflozin, or insulin.</p><p><strong>What is type 2 diabetes?</strong></p><p>Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zylinamet &nbsp;&nbsp;</strong></p><p>&bull; if you are allergic to linagliptin or metformin or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; if you have severely reduced kidney function.</p><p>&bull; if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see &ldquo;Risk of lactic acidosis&rdquo; below) or ketoacidosis. Ketoacidosis is a condition in which substances called &lsquo;ketone bodies&rsquo; accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual fruity smell.</p><p>&bull; if you ever had a diabetic pre-coma.</p><p>&bull; if you have a severe infection such as an infection affecting your lung or bronchial system or your kidney. Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&#39;).</p><p>&bull; if you have lost a lot of water from your body (dehydration), e.g. due to long-lasting or severe diarrhoea, or if you have vomited several times in a row. Dehydration may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&#39;).</p><p>&bull; if you are treated for acute heart failure or have recently had a heart attack, have severe problems with your circulation (such as shock) or have breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&#39;).</p><p>&bull; if you have liver problems.</p><p>&bull; if you drink alcohol to excess, either every day or only from time to time (see section &#39;Zylinamet with alcohol&#39;).</p><p>Do not take Zylinamet if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Zylinamet</p><p>&bull; if you have type 1 diabetes (your body does not produce any insulin). Zylinamet should not be used to treat this condition.</p><p>&bull; if you are taking insulin or an anti-diabetic medicine known as &lsquo;sulphonylurea&rsquo;, your doctor may want to reduce your dose of insulin or sulphonylurea when you take either of them together with Zylinamet in order to avoid low blood sugar (hypoglycaemia).</p><p>&bull; if you have or have had a disease of the pancreas.</p><p>If you have symptoms of acute pancreatitis, like persistent, severe abdominal pain, you should consult your doctor.</p><p>If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid. Your doctor may ask you to stop Zylinamet.</p><p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before taking Zylinamet.</p><p>Diabetic skin problems are a common complication of diabetes. You are advised to follow the recommendations for skin and foot care that you are given by your doctor or nurse.</p><p><strong>Risk of lactic acidosis.</strong></p><p>Due to the metformin component, Zylinamet may cause a very rare, but very serious complication called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).</p><p>If any of the above apply to you, talk to your doctor for further instructions.</p><p><strong>Stop taking Zylinamet for a short time if you have a condition that may be associated with dehydration</strong><strong> </strong>(significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instruction.</p><p><strong>Stop taking Zylinamet and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis</strong><strong>,</strong> as this condition may lead to coma.</p><p>Symptoms of lactic acidosis include:</p><p>&bull; vomiting</p><p>&bull; stomach ache (abdominal pain)</p><p>&bull; muscle cramps</p><p>&bull; a general feeling of not being well with severe tiredness</p><p>&bull; difficulty in breathing</p><p>&bull; reduced body temperature and heartbeat</p><p>Lactic acidosis is a medical emergency and must be treated in a hospital.</p><p>If you need to have major surgery you must stop taking Zylinamet during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with Zylinamet.</p><p>During treatment with Zylinamet, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.</p><p><strong>Children and adolescents </strong></p><p>This medicine is not recommended for use in children and adolescents under 18 years.</p><p><strong>Other medicines and Zylinamet</strong></p><p>If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Zylinamet before or at the time of the injection. Your doctor will decide when you must stop and when to restart your treatment with Zylinamet.</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Zylinamet. It is especially important to mention the following:</p><p>&bull; medicines which increase urine production (diuretics)</p><p>&bull; medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib)</p><p>&bull; certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists)</p><p>&bull; medicines that may change the amount of metformin in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, crizotinib, olaparib).</p><p>&bull; carbamazepine, phenobarbital or phenytoin. These may be used to control fits (seizures) or chronic pain.</p><p>&bull; rifampicin. This is an antibiotic used to treat infections such as tuberculosis.</p><p>&bull; medicines used to treat diseases that involve inflammation, like asthma and arthritis (corticosteroids).</p><p>&bull; bronchodilators (&beta;-sympathomimetics) for the treatment of bronchial asthma.</p><p>&bull; alcohol-containing medicines.</p><p><strong>Zylinamet with alcohol</strong><strong> </strong></p><p>Avoid excessive alcohol intake while taking Zylinamet since this may increase the risk of lactic acidosis (see section &lsquo;Warnings and precautions&rsquo;).</p><p><strong>&nbsp;Pregnancy</strong><strong>, </strong><strong>breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You should not use Zylinamet if you are pregnant. It is unknown if this medicine is harmful to the unborn child.</p><p>Metformin passes into human milk in small amounts. It is not known whether linagliptin passes into human milk. Talk to your doctor if you want to breast-feed while taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>Zylinamet has no or negligible influence on the ability to drive and use machines.</p><p>However, taking Zylinamet in combination with medicines called sulphonylureas or with insulin can cause too low blood sugar level (hypoglycaemia), which may affect your ability to drive and use machines or work without safe foothold.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take </strong></p><p>The amount of Zylinamet that you will take varies depending on your condition and the doses you currently take of metformin and/or individual tablets of linagliptin and metformin. Your doctor will tell you exactly the dose of this medicine to take.</p><p><strong>How to take this medicine</strong></p><p>&bull; one tablet twice daily by mouth in the dose prescribed by your doctor.</p><p>&bull; with meals to lower your chance of an upset stomach.</p><p>You should not exceed the maximum recommended daily dose of 5 mg linagliptin and 2,000 mg metformin hydrochloride.</p><p>Continue to take Zylinamet as long as your doctor prescribes it so you can continue to help control your blood sugar. Your doctor may prescribe this medicine together with another oral anti-diabetic medicine or insulin. Remember to take all medicines as directed by your doctor to achieve the best results for your health.</p><p>You should continue your diet during treatment with Zylinamet and take care that your carbohydrate intake is equally distributed over the day. If you are overweight, continue your energy-restricted diet as instructed. This medicine alone is unlikely to cause abnormally low blood sugar (hypoglycaemia). When Zylinamet is used with a sulphonylurea medicine or with insulin, low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea or insulin.</p><p><strong>If you take more Zylinamet than you should </strong></p><p>If you take more Zylinamet tablets than you should have, you may experience lactic acidosis. Symptoms of lactic acidosis are non-specific such as feeling or being very sick, vomiting, stomach ache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and heartbeat<strong>. If this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma. Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 2). Take the medicine pack with you.</strong><strong> </strong></p><p><strong>If you forget to take Zylinamet </strong></p><p>If you forget to take a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. Never take two doses at the same time (morning or evening).</p><p><strong>If you stop taking Zylinamet </strong></p><p>Keep taking Zylinamet until your doctor tells you to stop. This is to help keep your blood sugar under control.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some symptoms need immediate medical attention </strong></p><p>You should stop taking Zylinamet and see your doctor straight away if you experience the following symptoms of low blood sugar (hypoglycaemia): trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change, or confusion. Hypoglycaemia (frequency very common (may affect more than 1 in 10 people)) is an identified side effect for the combination of Zylinamet plus sulphonylurea and for the combination Zylinamet plus insulin.</p><p>Zylinamet may cause a very rare (may affect up to 1 user in 10,000), but very serious side effect called lactic acidosis (see section &lsquo;Warnings and precautions&rsquo;). If this happens you must <strong>stop</strong><strong> </strong><strong>taking Zylinamet and contact a doctor or the nearest hospital immediately</strong>, as lactic acidosis may lead to coma.</p><p>Some patients have experienced inflammation of the pancreas (pancreatitis; frequency rare, may affect up to 1 in 1000 people).</p><p>STOP taking Zylinamet and contact a doctor immediately if you notice any of the following serious side effects:</p><p>&bull; Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).</p><p><strong>Other side effects of Zylinamet include: </strong></p><p>Some patients have experienced allergic reactions (frequency rare), which may be serious, including wheezing and shortness of breath (bronchial hyperreactivity; frequency uncommon (may affect up to 1 in 100 people)). Some patients experienced rash (frequency uncommon), hives (urticaria; frequency rare), and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing (angioedema; frequency rare). If you experience any of the signs of illness mentioned above, stop taking Zylinamet and call your doctor right away. Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.</p><p>Some patients have had the following side effects while taking Zylinamet:</p><p>&bull; <strong>Common (may affect up to 1 in 10 people):</strong> diarrhoea, blood enzyme increase (lipase increase), feeling sick (nausea)</p><p><strong>&bull; Uncommon:</strong> inflamed nose or throat (nasopharyngitis), cough, loss of appetite (decreased appetite), being sick (vomiting), blood enzyme increase (amylase increase), itching (pruritus)</p><p>&bull; <strong>Rare:</strong> blistering of skin (bullous pemphigoid)</p><p>Some patients have experienced the following side effects while taking Zylinamet with insulin</p><p>&bull; <strong>Uncommon:</strong> liver function disorders, constipation</p><p><strong>Side effects when taking metformin alone, that were not described for Zylinamet: </strong></p><p>&bull; <strong>Very common:</strong> abdominal pain.</p><p>&bull; <strong>Common (may affect up to 1 in 10 people):</strong> a metallic taste (taste disturbance).</p><p><strong>&bull; Very rare (may affect up to 1 in 10,000 people):</strong> decreased vitamin B12 levels, hepatitis (a problem with your liver), skin reaction as redness of the skin (erythema).</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any possible side effects not listed in this leaflet, please tell your doctor or pharmacist. You can also report side effects directly (see section 6). By reporting side effects you can help provide more information on the safety of this medicine.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: &nbsp;&nbsp;&nbsp;npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep Zylinamet tablets out of the sight and reach of children.</p><p>&bull; Do not use them after the expiry date that is printed on the pack after &ldquo;EXP:&rdquo;. The expiry date refers to the last day of that month.</p><p>&bull; Store below 30 &deg;C.</p><p>&bull; Store in the original package in order to protect from moisture.</p><p>&bull; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zylinamet contains</strong></p><p><strong>The active substances are</strong> Linagliptin and Metformin HCL</p><p>&bull; Each Zylinamet 2.5 mg/500 mg film-coated tablet contains 2.5 mg of linagliptin and 500 mg of metformin hydrochloride.</p><p>&bull; Each Zylinamet 2.5 mg/850 mg film-coated tablet contains 2.5 mg of linagliptin and 850 mg of metformin hydrochloride.</p><p>&bull; Each Zylinamet 2.5 mg/1000 mg film-coated tablet contains 2.5 mg of linagliptin and 1,000 mg of metformin hydrochloride.</p><p><strong>The other ingredients are</strong> Maize starch, Co Povidone, Colloidal Silicon Dioxide, Magnesium Stearate, Opadry Yellow (Zylinamet 2.5 mg /500 mg), Opadry Beige (Zylinamet 2.5 mg/850 mg) and Opadry Pink (Zylinamet 2.5 mg/1000 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zylinamet 2.5 mg/500 mg film-coated tablets are yellow color, oval biconvex shaped, film coated tablets embossed with “S2” on one side and plain on the other side.
Zylinamet 2.5 mg/850 mg film-coated tablets are beige color, oval biconvex shaped, film coated tablets embossed with “S3” on one side and plain on the other side.
Zylinamet 2.5 mg/1000 mg film-coated tablets are pink color, oval biconvex shaped, film coated tablets embossed with “S4” on one side and plain on the other side.
Zylinamet film-coated tablets are available in blister packs containing 7 tablets and each box contains eight blisters (56 tablets).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Alrai Pharmaceutical Industries Co. (L.L.C.)</strong></p><p>Al Wadi, Building No. 2684, Additional No. 6236</p><p>Unit No. 1, Jeddah 22518 Almu&rsquo;tasem Bellah Al Fatemy Street</p><p>P.O.Box: 9224 Jeddah - 21413 Kingdom of Saudi Arabia</p><p><u>Tel</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966 12 2888949</p><p><u>E-mail:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; info@alraipharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم دواءك هو زيليناميت، و يحتوي على مادتين فعالتين هما ليناجليبتين و هيدروكلوريد الميتفورمين</p><p dir="RTL">&bull; ليناجليبتين ينتمي&nbsp; إلى مجموعة من الأدوية تسمى مثبطات ثنائي ببتيديل ببتيداز-4</p><p dir="RTL">&bull; الميتفورمين ينتمي إلى مجموعة من الأدوية تسمى البيغوانيد.</p><p dir="RTL"><strong>كيف يعمل زيليناميت</strong></p><p dir="RTL">المادتين الفعالتين يعملان معاً للسيطرة على مستوى سكر الدم في المرضى البالغين الذين يعانون من مرض السكري من النوع الثاني. إلى جانب النظام الغذائي وممارسة الرياضة، هذا الدواء يساعد على تحسين مستويات وتأثيرات الأنسولين بعد الأكل ويقلل من كمية السكر التي يصنعها جسمك.</p><p dir="RTL">يمكن استخدام هذا الدواء بمفرده أو مع بعض الأدوية الأخرى لمرض السكري مثل سلفونيل يوريا أو امباجليفلوزين أو الأنسولين.</p><p dir="RTL"><strong>ما هو مرض السكري من النوع الثاني؟</strong></p><p dir="RTL">داء السكري من النوع الثاني هو حالة لا يُنتج فيها جسمك ما يكفي من الأنسولين، والأنسولين الذي ينتجه جسمك لا يعمل كما ينبغي. كما يمكن لجسمك أيضًا إنتاج الكثير من السكر. عندما يحدث هذا، يتراكم السكر في الدم. مما قد يؤدي إلى مشاكل صحية خطيرة مثل أمراض القلب وأمراض الكلى والعمى وبتر الأطراف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تأخذ زيليناميت</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسية تجاه ليناجليبتين أو الميتفورمين أو أي من مكونات زيليناميت الأخرى (المذكورة في القسم 6).</p><p dir="RTL">&bull; إذا كنت تعاني من قصور شديد في وظائف الكلى.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض السكري غير المنضبط، على سبيل المثال، فرط سكر الدم الشديد (ارتفاع السكر في الدم)، والغثيان، والقيء، والإسهال، وفقدان الوزن السريع، و الحمض اللاكتيكي (انظر &quot;خطر الحمض اللاكتيكي&quot; أدناه) أو الحمض الكيتوني. الحمض الكيتوني هو حالة تتراكم فيها مواد تسمى &quot;الأجسام الكيتونية&quot; في الدم ويمكن أن تؤدي إلى حدوث الأعراض التي تسبق غيبوبة السكري. تشمل الأعراض آلام المعدة، والتنفس السريع والعميق، والنعاس، أو ظهور رائحة فاكهيه غير معتادة في الفم.</p><p dir="RTL">&bull; إذا كنت قد أُصِبت سابقًا بالأعراض التي تسبق غيبوبة السكري.</p><p dir="RTL">&bull; إذا كنت تعاني من عدوى شديدة مثل العدوى التي تصيب الرئة أو الشعب الهوائية أو الكلى. قد تؤدي العدوى الشديدة إلى مشاكل في الكلى، مما قد يعرضك لخطر الإصابة بالحمض اللاكتيكي (انظر &quot;المحاذير والاحتياطات&quot;).</p><p dir="RTL">&bull; إذا فقدت الكثير من الماء من جسمك (الجفاف)، على سبيل المثال بسبب الإسهال طويل الأمد أو الشديد، أو إذا تقيأت عدة مرات متتالية. قد يؤدي الجفاف إلى مشاكل في الكلى، مما قد يعرضك لخطر الإصابة بالحمض اللاكتيكي (انظر &quot;المحاذير والاحتياطات&quot;).</p><p dir="RTL">&bull; إذا كنت تتعالج من قصور القلب الحاد أو تعرضت مؤخرًا لنوبة قلبية، أو لديك مشاكل خطيرة في الدورة الدموية (مثل الصدمة) أو تعاني من صعوبات في التنفس. قد يؤدي ذلك إلى نقص في إمداد الأنسجة بالأكسجين مما قد يعرضك لخطر الإصابة بالحمض اللاكتيكي&nbsp; (انظر &quot;المحاذير والاحتياطات&quot;).</p><p dir="RTL">&bull; إذا كان لديك مشاكل في الكبد.</p><p dir="RTL">&bull; إذا كنت تشرب الكحول بكثرة، إما كل يوم أو فقط من وقت لآخر (انظر قسم &quot;تناول زيليناميت مع الكحول&quot;).</p><p dir="RTL">لا تأخذ زيليناميت إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول زيليناميت</p><p dir="RTL">&bull; إذا كنت مصابًا بداء السكري من النوع الأول (لا ينتج جسمك أي أنسولين). لا ينبغي استخدام زيليناميت لعلاج هذه الحالة.</p><p dir="RTL">&bull; إذا كنت تتناول الأنسولين أو دواءً مضادًا لمرض السكري يُعرف باسم &quot;سلفونيل يوريا&quot;، فقد يرغب طبيبك في تقليل جرعتك من الأنسولين أو سلفونيل يوريا عند تناول أي منهما مع زيليناميت لتجنب انخفاض نسبة السكر في الدم (نقص سكر الدم).</p><p dir="RTL">&bull; إذا كنت تعاني أو عانيت في السابق من مرض في البنكرياس.</p><p dir="RTL">إذا كنت تعاني من أعراض التهاب البنكرياس الحاد، مثل آلام البطن الشديدة والمستمرة، فعليك استشارة الطبيب.</p><p dir="RTL">إذا واجهت تقرحات في الجلد فقد تكون علامة على حالة تسمى الفقاع الفقاعي. قد يطلب منك طبيبك إيقاف زيليناميت.</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان أي مما سبق ينطبق عليك، فتحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول زيليناميت.</p><p dir="RTL">تعد مشاكل الجلد السكرية من المضاعفات الشائعة لمرض السكري. يُنصح باتباع التوصيات الخاصة بالعناية بالبشرة والقدم التي يقدمها لك طبيبك أو ممرضك.</p><p dir="RTL"><strong>خطر الحمض اللاكتيكي</strong></p><p dir="RTL">قد يتسبب زيليناميت في حدوث أعراض جانبية نادرة جدًا ولكنها خطرة جدًا تسمى الحمض اللاكتيكي، خاصة إذا كانت كليتيك لا تعملان بشكل صحيح. يزداد خطر الإصابة بالحمض اللاكتيكي بسبب مرض السكري غر المنضبط، الالتهابات الخطيرة، وعدم الأكل لفترة طويلة أو تناول الكحول، الجفاف (لمزيد من المعلومات أنظر أدناه)، مشاكل في الكبد وأي حالات طبية يكون فيها جزء من الجسم يعاني من نقص في إمدادات الأوكسجين (مثل أمراض القلب الحادة).</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك، فتحدث إلى طبيبك للحصول على مزيد من التعليمات.</p><p><strong>توقف عن تناول زيليناميت لفترة قصيرة إذا كنت تعاني من حالة قد تترافق مع الجفاف </strong>(فقدان كبير لسوائل الجسم) مثل القيء الشديد أو الإسهال أو الحمى أو التعرض للحرارة أو إذا كنت تشرب سوائل أقل من المعتاد. تحدث إلى طبيبك لمزيد من التعليمات.</p><p dir="RTL"><strong>توقف عن تناول</strong><strong> </strong><strong>زيليناميت</strong><strong> </strong><strong>واتصل بالطبيب أو أقرب مستشفى على الفور إذا واجهت بعض أعراض الحمض اللاكتيكي، </strong>لأن هذه الحالة قد تؤدي إلى غيبوبة. تشمل أعراض الحمض اللاكتيكي ما يلي:</p><p dir="RTL">&bull; &nbsp;القيء</p><p dir="RTL">&bull; &nbsp;آلام في المعدة (ألم في البطن)</p><p dir="RTL">&bull; &nbsp;تشنجات العضلات</p><p dir="RTL">&bull; &nbsp;شعور عام بأنك لست على ما يرام مع التعب الشديد</p><p dir="RTL">&bull; &nbsp;صعوبة في التنفس</p><p dir="RTL">&bull; &nbsp;انخفاض درجة حرارة الجسم وضربات القلب</p><p dir="RTL">&nbsp;يعد الحمض اللاكتيكي حالة طبية طارئة ويجب معالجتها في المستشفى.</p><p dir="RTL">إذا كنت بحاجة إلى إجراء عملية جراحية كبرى، يجب عليك التوقف عن تناول زيليناميت أثناء العملية ولبعض الوقت بعدها. سيقرر طبيبك متى يجب أن تتوقف ومتى تستأنف العلاج بـ &nbsp;زيليناميت</p><p dir="RTL">أثناء العلاج بـ &nbsp;زيليناميت، سيقوم طبيبك بفحص وظائف الكلى مرة واحدة على الأقل في السنة أو بشكل متكرر إذا كنت مسنًا و / أو إذا كنت تعاني من تدهور وظائف الكلى.</p><p><strong>الأطفال والمراهقون</strong></p><p>لا ينصح باستخدام هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا<strong>.</strong></p><p dir="RTL"><strong>زيليناميت والأدوية الاخرى</strong></p><p dir="RTL">إذا كنت تحتاج لحقنة في الدم بالمحلول المشع الذي يحتوي على الأيودين بغرض الخضوع للأشعة السينية، يجب عليك التوقف عن تناول زيليناميت قبل أو في وقت الحقن. سيقرر طبيبك متى يجب أن تتوقف ومتى ستستأنف علاجك مع زيليناميت.</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. قد تحتاج إلى اختبار وظائف الكلى ومستوى الجلوكوز في الدم بشكل متكرر، أو قد يحتاج طبيبك إلى ضبط جرعة زيليناميت. من المهم بشكل خاص ذكر ما يلي:</p><p dir="RTL">&bull;&nbsp; الأدوية (التي تؤخذ عن طريق الفم، الاستنشاق أو الحقن) والتي تستخدم لعلاج الأمراض الي تحتوي على التهابات، مثل الربو والتهاب المفاصل (الستيرويدات).</p><p dir="RTL">&bull;&nbsp; الأدوية التي تؤدي إلى زيادة إنتاج البول (مدرات البول).</p><p dir="RTL">&bull;&nbsp; الأدوية المستخدمة لعلاج الألم والالتهابات (المثبطات الغير ستيرويدية و مثبطات كوكس-2 )، مثل الإيبوبروفين والسيليكوكسيب).</p><p dir="RTL">&bull;&nbsp; بعض الأدوية المعينة لعلاج ارتفاع ضغط الدم (مثبطات الإنزيم المحول للانجيوتنسين ومضادات مستقبلات الأنجيوتنسن &nbsp;II).</p><p dir="RTL">&bull; الأدوية التي قد تغير كمية الميتفورمين في الدم، خاصة إذا كنت تعاني من ضعف وظائف الكلى (مثل فيراباميل، ريفامبيسين، سيميتيدين، دولوتغرافير، رانولازين، تريميثوبريم، فانديتانيب، إيزافوكونازول، كريزوتينيب ، أولاباريب).</p><p dir="RTL">&bull; كاربامازيبين، فينوباربيتال أو فينيتوين. يمكن استخدام هذه الأدوية للسيطرة على النوبات (الصرع) أو الألم المزمن.</p><p dir="RTL">&bull; &nbsp;ريفامبيسين. هذا مضاد حيوي يستخدم لعلاج امراض العدوى مثل السل.</p><p dir="RTL">&bull; الأدوية المستخدمة لعلاج الإلتهاب، مثل الربو والتهاب المفاصل (الكورتيكوستيرويدات).</p><p dir="RTL">&bull; موسعات الشعب الهوائية (المحاكيات الودية) لعلاج الربو القصبي.</p><p dir="RTL">&bull; الأدوية التي تحتوي على الكحول.</p><p><strong>تناول زيليناميت مع الكحول </strong></p><p dir="RTL">تجنب الإفراط في تناول الكحول أثناء تناول زيليناميت لأن ذلك قد يزيد من خطر الإصابة بالحمض اللاكتيكي (انظر &quot;المحاذير والاحتياطات&quot;).</p><p dir="RTL"><strong>الحمل والرضاعة</strong><strong> </strong><strong>والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة، تعتقدين أنك حامل أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">يجب ألا تتناولي زيليناميت إذا كنتِ حاملاً. من غير المعروف ما إذا كان هذا الدواء ضارًا بالجنين.</p><p dir="RTL">يمر الميتفورمين من خلال حليب الأم بكميات صغيرة. من غير المعروف ما إذا كان ليناجليبتين يمر في حليب الأم. تحدثي إلى طبيبك إذا كنتِ ترغبين في الرضاعة الطبيعية أثناء تناول هذا الدواء.</p><p dir="RTL"><strong>تأثير زيليناميت على القيادة واستخدام الآلات</strong></p><p>زيليناميت ليس له تأثير أو تأثيره لا يذكر في القدرة على القيادة واستخدام الآلات.</p><p>ومع ذلك، فإن تناول زيليناميت مع أدوية تسمى سلفونيل يوريا أو مع الأنسولين يمكن أن يؤدي إلى انخفاض شديد في مستوى السكر في الدم، مما قد يؤثر في قدرتك على القيادة واستخدام الآلات أو العمل دون موطئ قدم آمن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما هو موصوف في هذه النشرة أو كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p><strong>الكمية التي يجب أن تتناولها من هذا الدواء </strong></p><p>الكمية التي ستتناولها من زيليناميت تختلف حسب حالتك و على حسب الجرعات التي تتناولها في الوقت الحالي من الميتفورمين و/أو اليناجليبتين مع الميتفورمين. طبيبك سيخبرك عن الجرعة المناسبة لتناولها من هذا الدواء.</p><p><strong>كيف تتناول هذا الدواء</strong></p><p>&nbsp;حبة واحدة مرتين في اليوم عن طريق الفم بكمية الجرعة التي حددها الطبيب. &bull;</p><p dir="RTL">&bull; مع الطعام لتقليل احتمال اضطراب المعدة.</p><p>يجب ألا تتجاوز الجرعة اليومية القصوى الموصى بها وهي 5 ملجم ليناجليبتين و 2000 ملجم هيدروكلوريد الميتفورمين.</p><p>أستمر في تناول زيليناميت طالما وصفه لك طبيبك حتى تتمكن من الاستمرار في ضبط سكر الدم. قد يصف لك طبيبك هذا الدواء مع ادوية سكر اخرى عن طريق الفم أو مع الانسولين. تذكر أن تتناول الدواء كما أخبرك طبيبك لتحصل على أفضل النتائج.</p><p>يجب أن تستمر في نظامك الغذائي أثناء العلاج بـ زيليناميت وأن تحرص على توزيع كمية الكربوهيدرات الخاصة بك بالتساوي على مدار اليوم. إذا كنت تعاني من زيادة الوزن، فاستمر في نظامك الغذائي وفقًا للتعليمات. من غير المحتمل أن يتسبب هذا الدواء وحده في انخفاض نسبة السكر في الدم بشكل غير طبيعي (نقص سكر الدم). عند استخدام زيليناميت مع دواء سلفونيل يوريا أو مع الأنسولين، يمكن أن يحدث انخفاض في نسبة السكر في الدم وقد يقلل طبيبك من جرعة السلفونيل يوريا أو الأنسولين.</p><p dir="RTL"><strong>إذا تناولت زيليناميت أكثر من اللازم</strong></p><p>إذا تناولت أقراص زيليناميت أكثر مما يلزم، فقد تصاب بالحمض اللاكتيكي. أعراض الحمض اللاكتيكي غير محددة مثل الشعور أو المرض الشديد والقيء وآلام المعدة مع تقلصات العضلات والشعور العام بعدم الراحة مع التعب الشديد وصعوبة التنفس. تتمثل الأعراض الأخرى في انخفاض درجة حرارة الجسم وضربات القلب. إذا حدث هذا لك، فقد تحتاج إلى علاج فوري في المستشفى، حيث يمكن أن يؤدي الحمض اللاكتيكي إلى غيبوبة. توقف عن تناول هذا الدواء فورًا واتصل بالطبيب أو أقرب مستشفى على الفور (انظر القسم 2). خذ علبة الدواء معك.</p><p>إذا نسيت أن تتناول زيليناميت</p><p dir="RTL">إذا نسيت أن تأخذ جرعة، فتناولها بمجرد أن تتذكرها. ومع ذلك، إذا اقترب موعد الجرعة التالية، فتجاوز الجرعة الفائتة. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية. لا تأخذ جرعتين في نفس الوقت (صباحًا أو مساءً).</p><p dir="RTL"><strong>إذا توقفت عن تناول زيليناميت </strong></p><p dir="RTL">استمر في أخذ زيليناميت حتى يخبرك طبيبك بالتوقف. وذلك للمساعدة في الحفاظ على نسبة السكر في الدم لديك تحت السيطرة.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>تحتاج بعض الأعراض إلى عناية طبية فورية</p><p>يجب عليك التوقف عن تناول زيليناميت واستشارة طبيبك على الفور إذا كنت تعاني من الأعراض التالية لانخفاض نسبة السكر في الدم: الارتعاش، والتعرق، والقلق، وعدم وضوح الرؤية، وخز الشفاه، والشحوب، وتغير المزاج، أو الارتباك. نقص سكر الدم (التردد: شائع جدًا (قد تؤثر على أكثر من شخص من كل 10 أشخاص)) هو أحد الآثار الجانبية المحددة عند الجمع بين زيليناميت مع سلفونيل يوريا و جمع زيليناميت مع الأنسولين.</p><p>قد يتسبب زيليناميت في حدوث حالة نادرة جدًا (قد تؤثر على ما يصل إلى شخص من بين 10000 شخص)، لكن الآثار الجانبية الخطيرة جدًا تسمى الحمض اللاكتيكي (انظر قسم &quot;المحاذير والاحتياطات&quot;). إذا حدث هذا، يجب عليك التوقف عن تناول زيليناميت والاتصال بالطبيب أو أقرب مستشفى على الفور، لأن الحمض اللاكتيكي قد يؤدي إلى غيبوبة.</p><p>عانى بعض المرضى من التهاب في البنكرياس (التهاب البنكرياس؛ نادر الحدوث، قد يؤثر على شخص من كل 1000 شخص).</p><p>توقف عن تناول زيليناميت واتصل بالطبيب على الفور إذا لاحظت أيًا من الأعراض الجانبية الخطيرة التالية:</p><p>&bull; ألم حاد ومستمر في البطن (منطقة المعدة) والذي قد يصل إلى ظهرك، بالإضافة إلى الغثيان والقيء، حيث يمكن أن يكون علامة على التهاب البنكرياس.</p><p>تشمل الآثار الجانبية الأخرى لـ زيليناميت ما يلي:</p><p>عانى بعض المرضى من ردود فعل تحسسية (التكرار: نادر)، والتي قد تكون خطيرة، بما في ذلك الصفير وضيق التنفس (فرط نشاط القصبات ؛ وتكرارها غير شائع (قد يؤثر على شخص من كل 100 شخص). عانى بعض المرضى من طفح جلدي (التكرار: غير شائع) وخلايا النحل (الشرى؛ التكرار: نادر) وانتفاخ في الوجه والشفتين واللسان والحلق الذي قد يسبب صعوبة في التنفس أو البلع (وذمة وعائية ؛ التكرار: نادر). إذا واجهت أيًا من علامات المرض المذكورة أعلاه، فتوقف عن تناول زيليناميت واتصل بطبيبك على الفور. قد يصف لك طبيبك دواءً لعلاج رد الفعل التحسسي لديك ودواء مختلف لمرض السكري لديك.</p><p>عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول زيليناميت:</p><p>&bull; شائعة (قد تؤثر على شخص من كل 10 أشخاص): إسهال، زيادة إنزيم الدم (زيادة الليباز) ، الشعور بالغثيان.</p><p>&bull; غير شائعة: التهاب الأنف أو الحلق (التهاب البلعوم الأنفي) ، والسعال، وفقدان الشهية (انخفاض الشهية) ، الشعور بالمرض (القيء)، وزيادة إنزيم الدم (زيادة الأميليز) ، والحكة</p><p>&bull; نادرة: ظهور تقرحات في الجلد (شبيه الفقاع الفقاعي).</p><p>عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول زيليناميت مع الأنسولين</p><p>&bull; غير شائعة: إضطرابات في وظائف الكبد، إمساك.</p><p>أعراض جانبية عند تناول الميتفورمين بمفرده، والتي لم يتم وصفها لزيليناميت:</p><p>&bull; شائعة جدًا: آلام في البطن.</p><p>&bull; شائعة (قد تؤثر على شخص من كل 10 أشخاص): طعم معدني (اضطراب في الذوق).</p><p>&bull; نادرة جدًا (قد تؤثر على شخص من بين 10000 شخص): انخفاض مستويات فيتامين ب 12، التهاب الكبد، تفاعل جلدي مثل احمرار الجلد.</p><p dir="RTL"><strong>التبليغ عن الأعراض الجانبية</strong></p><p dir="RTL">في حال زادت الأعراض الجانبية سوءً أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، قم بالتواصل مع الطبيب أو الصيدلي. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً (انظر القسم 6). عن طريق الإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&bull;</strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد :&nbsp;&nbsp; &nbsp;19999</p><p dir="RTL">البريد الإلكتروني:&nbsp;&nbsp; &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني https://ade.sfda.gov.sa :</p><p dir="RTL"><strong>&bull;</strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; احفظ أقراص زيليناميت بعيدًا عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدمها بعد تاريخ انتهاء الصلاحية المطبوع على العبوة بعد &quot;:EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull; يحفظ في درجة حرارة أقل من 30 &deg;م.</p><p dir="RTL">&bull; يجب التخزين في العلبة الأصلية من أجل الحماية من الرطوبة.</p><p dir="RTL">&bull; يجب عدم التخلص من الأدوية في مياه الصرف أو مع مخلفات المنزل. أسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الإجراءات ستساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المواد الفعالة هي</strong><strong>:</strong> ليناجليبتين و هيدروكلوريد الميتفورمين.</p><p dir="RTL">&bull; كل قرص زيليناميت 2.5 ملجم / 500 ملجم مغلف يحتوي على 2.5 ملجم ليناجليبتين و 500 ملجم من هيدروكلوريد الميتفورمين.</p><p dir="RTL">&bull; كل قرص زيليناميت 2.5 ملجم / 850 ملجم مغلف يحتوي على 2.5 ملجم من ليناجليبتين و 850 ملجم من هيدروكلوريد الميتفورمين.</p><p dir="RTL">&bull; كل قرص زيليناميت 2.5 ملجم / 1000 ملجم مغلف يحتوي على 2.5 ملجم ليناجليبتين و 1000 ملجم من هيدروكلوريد الميتفورمين.</p><p dir="RTL"><strong>المكونات الأخرى هي:</strong> نشا الذرة ، كوبوفيدون ، ثاني أكسيد السيليكون ، ستيرات المغنيسيوم ، أوبادري أصفر (زيليناميت 2.5 ملجم / 500 ملجم) ، أوبادري بيج (زيليناميت 2.5 ملجم / 850 ملجم) و أوبادري وردي (زيليناميت 2.5 ملجم / 1000 ملجم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو زيليناميت وما هي محتويات العبوة</strong></p><p dir="RTL"><strong><u>زيليناميت 2.5 ملجم / 500 ملجم، أقراص مغلفة غشائيًا:</u></strong></p><p dir="RTL">أقراص صفراء اللون مغلفة غشائيًا بيضاوية الشكل محدبة من الجهتين منقوش عليها &rdquo; S2&rdquo; من جانب ولا يوجد نقش على الجانب الآخر.</p><p dir="RTL"><strong><u>زيليناميت 2.5 ملجم / 850 ملجم، أقراص مغلفة غشائيًا:</u></strong></p><p dir="RTL">أقراص لونها بيج مغلفة غشائيًا بيضاوية الشكل محدبة من الجهتين منقوش عليها &rdquo;S3&rdquo; من جانب ولا يوجد نقش على الجانب الآخر.</p><p dir="RTL"><strong><u>زيليناميت 2.5 ملجم / 1000 ملجم، أقراص مغلفة غشائيًا:</u></strong></p><p dir="RTL">أقراص وردية اللون مغلفة غشائيًا بيضاوية الشكل محدبة من الجهتين منقوش عليها &rdquo;S4&rdquo; من جانب ولا يوجد نقش على الجانب الآخر.</p><p dir="RTL">تتوفر <strong>أقراص زيليناميت </strong>في شريط يحتوي على 7 أقراص وتحتوي كل علبة على ثمان أشرطة (56 قرص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة مصنع الرأي للصناعات الدوائية(ذ.م.م.)</p><p dir="RTL">الوادي، مبنى رقم 2684 ، الرقم الإضافي 6236 ، وحدة رقم 1</p><p dir="RTL">جدة 22518 شارع المعتصم بالله الفاطمي.</p><p dir="RTL">صندوق بريد: 9224 جدة - ٢١٤١٣ المملكة العربية السعودية</p><p dir="RTL">تلفون:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;122888949 966+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p dir="RTL">ايميل:&nbsp; Info@alraipharma.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zylinamet 2.5 mg/500 mg film-coated tablets
Zylinamet 2.5 mg/850 mg film-coated tablets
Zylinamet 2.5 mg/1,000 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zylinamet 2.5 mg/500 mg film-coated tablets
Each tablet contains 2.5 mg of linagliptin and 500 mg of metformin hydrochloride.
Zylinamet 2.5 mg/850 mg film-coated tablets
Each tablet contains 2.5 mg of linagliptin and 850 mg of metformin hydrochloride.
Zylinamet 2.5 mg/1,000 mg film-coated tablets
Each tablet contains 2.5 mg of linagliptin and 1,000 mg of metformin hydrochloride.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Zylinamet 2.5 mg/500 mg film-coated tablets
Yellow color biconvex oval shaped, film coated tablets, embossed with ′S2` on one side and plain on the other side. 
Zylinamet 2.5 mg/850 mg film-coated tablets
Beige color biconvex oval shaped, film coated tablets, embossed with ′S3` on one side and plain on the other side. 
Zylinamet 2.5 mg/1,000 mg film-coated tablets
Pink color biconvex oval shaped, film coated tablets, embossed with ′S4` on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zylinamet &nbsp;is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to</p><p>improve glycaemic control:</p><p>&bull; In patients inadequately controlled on their maximally tolerated dose of metformin alone</p><p>&bull; In combination with other medicinal products for the treatment of diabetes, including insulin, in</p><p>patients inadequately controlled with metformin and these medicinal products</p><p>&bull; In patients already being treated with the combination of linagliptin and metformin as separate tablets.</p><p>(see sections 4.4, 4.5 and 5.1 for available data on different combinations).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Adults with normal renal function (GFR &ge;90 ml/min)</em></p><p>The dose of antihyperglycaemic therapy with Zylinamet &nbsp;should be individualised on the basis of the patient&rsquo;s current regimen, effectiveness, and tolerability, while not exceeding the maximum recommended daily dose of 5 mg linagliptin plus 2,000 mg of metformin hydrochloride.</p><p><em>Patients inadequately controlled on maximal tolerated dose of metformin monotherapy</em></p><p>For patients not adequately controlled on metformin alone, the usual starting dose of Zylinamet &nbsp;should provide linagliptin dosed as 2.5 mg twice daily (5 mg total daily dose) plus the dose of</p><p>metformin already being taken.</p><p><em>Patients switching from co-administration of linagliptin and metformin</em></p><p>For patients switching from co-administration of linagliptin and metformin, Zylinamet &nbsp;should be initiated at the dose of linagliptin and metformin already being taken.</p><p><em>Patients inadequately controlled on dual combination therapy with the maximal tolerated dose of</em></p><p><em>metformin and a sulphonylurea</em></p><p>The dose of Zylinamet &nbsp;should provide linagliptin dosed as 2.5 mg twice daily (5 mg total daily dose) and a dose of metformin similar to the dose already being taken. When linagliptin plus metformin hydrochloride is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4).</p><p><em>Patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin</em></p><p>The dose of Zylinamet &nbsp;should provide linagliptin dosed as 2.5 mg twice daily (5 mg total daily dose) and a dose of metformin similar to the dose already being taken. When linagliptin plus metformin hydrochloride is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4).</p><p>For the different doses of metformin, Zylinamet &nbsp;is available in strengths of 2.5 mg linagliptin plus 850 mg metformin hydrochloride and 2.5 mg linagliptin plus 1,000 mg metformin hydrochloride.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>As metformin is excreted by the kidney, Zylinamet &nbsp;should be used with caution as age increases.</p><p>Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis,particularly in the elderly (see sections 4.3 and 4.4).</p><p><em>Renal impairment</em></p><p>A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.</p><p>Factors that may increase the risk of lactic acidosis (see 4.4) should be reviewed before considering initiation of metformin in patients with GFR&lt;60 ml/min.</p><p>If no adequate strength of Zylinamet &nbsp;is available, individual monocomponents should be used instead of the fixed dose combination.</p><p>Table 1:Posology for renally impaired patients</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>GFR ml/min</p></td><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>Linagliptin</p></td></tr><tr><td style="vertical-align:top"><p>60-89</p></td><td style="vertical-align:top"><p>Maximum daily dose is 3000 mg. Dose reduction may be considered in relation to declining renal function.</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>45-59</p></td><td style="vertical-align:top"><p>Maximum daily dose is 2000 mg The starting dose is at most half of the maximum dose.</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>30-44</p></td><td style="vertical-align:top"><p>Maximum daily dose is 1000 mg. The starting dose is at most half of the maximum dose.</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>&lt;30</p></td><td style="vertical-align:top"><p>Metformin is contraindicated</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr></tbody></table><p><em>Hepatic impairment</em></p><p>Zylinamet &nbsp;is not recommended in patients with hepatic impairment due to the active substance metformin (see sections 4.3 and 5.2). Clinical experience with Zylinamet &nbsp;in patients with hepatic impairment is lacking.</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Zylinamet &nbsp;in children and adolescents aged 0 to 18 years have not been established. No data are available.</p><p><u>Method of administration</u></p><p>Zylinamet &nbsp;should be taken twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin.</p><p>All patients should continue their diet with an adequate distribution of carbohydrate intake during the day. Overweight patients should continue their energy-restricted diet.</p><p>If a dose is missed, it should be taken as soon as the patient remembers. However, a double dose should not be taken at the same time. In that case, the missed dose should be skipped.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
• Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
• Diabetic pre-coma.
• Severe renal failure (GFR <30 ml/min).
• Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.
• Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock.
• Hepatic impairment, acute alcohol intoxication, alcoholism (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Zylinamet &nbsp;should not be used in patients with type 1 diabetes.</p><p><u>Hypoglycaemia</u></p><p>When linagliptin was added to a sulphonylurea on a background of metformin, the incidence of hypoglycaemia was increased over that of placebo.</p><p>Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when Zylinamet &nbsp;is used in combination with a sulphonylurea and/or insulin. A dose reduction of the sulphonylurea or insulin may be considered (see section 4.2).</p><p>Hypoglycaemia is not identified as adverse reaction for linagliptin, metformin, or linagliptin plus metformin. In clinical trials, the incidence rates of hypoglycemia were comparably low in patients taking linagliptin in combination with metformin or metformin alone.</p><p><u>Lactic acidosis</u></p><p>Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.</p><p>In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.</p><p>Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic impairment, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).</p><p>Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterised by acidotic dyspnea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt;7.35), increased plasma lactate levels (&gt;5 mmol/l) and an increased anion gap and lactate/pyruvate ratio.</p><p><u>Administration</u><u> </u><u>of iodinated contrast agent</u></p><p>Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5.</p><p><u>Renal function</u></p><p>GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2. Metformin is contraindicated in patients with GFR&lt;30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3).</p><p><u>Cardiac function</u></p><p>Patients with heart failure are more at risk of hypoxia and renal impairment. In patients with stable chronic heart failure, Zylinamet &nbsp;may be used with a regular monitoring of cardiac and renal function. For patients with acute and unstable heart failure, Zylinamet &nbsp;is contraindicated (see section 4.3).</p><p><u>Surgery</u></p><p>Metformin must be discontinued at the time of surgery under general, spinal or epidural anesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.</p><p><u>Elderly</u></p><p>Caution should be exercised when treating patients 80 years and older (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. However, such studies have been conducted with the individual active substances, i.e. linagliptin and metformin. Co-administration of multiple doses of linagliptin and metformin did not meaningfully alter the pharmacokinetics of either linagliptin or metformin in healthy volunteers and patients.</p><p>Linagliptin</p><p>In vitro assessment of interactions</p><p>Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. It is not an inducer of CYP isozymes.</p><p>Linagliptin is a P-glycoprotein substrate, and inhibits P-glycoprotein mediated transport of digoxin with low potency. Based on these results and in vivo drug interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates.</p><p>In vivo assessment of interactions</p><p><u>Effects of other medicinal products on linagliptin</u></p><p>Clinical data described below suggest that the risk for clinically meaningful interactions by coadministered medicinal products is low.</p><p>Metformin:</p><p>Co-administration of multiple three-times-daily doses of 850 mg metformin hydrochloride with 10 mg linagliptin once daily did not clinical meaningfully alter the pharmacokinetics of linagliptin in healthy subjects.</p><p>Sulphonylureas:</p><p>The steady-state pharmacokinetics of 5 mg linagliptin were not changed by concomitant administration of a single 1.75 mg dose glibenclamide (glyburide).</p><p>Ritonavir:</p><p>Co-administration of a single 5 mg oral dose of linagliptin and multiple 200 mg oral doses of ritonavir, a potent inhibitor of P-glycoprotein and CYP3A4, increased the AUC and Cmax of linagliptin approximately twofold and threefold, respectively. The unbound concentrations, which are usually less than 1% at the therapeutic dose of linagliptin, were increased 4-5-fold after co-administration with ritonavir. Simulations of steady-state plasma concentrations of linagliptin with and without ritonavir indicated that the increase in exposure will not be associated with an increased accumulation. These changes in linagliptin pharmacokinetics were not considered to be clinically relevant. Therefore, clinically relevant interactions would not be expected with other P-glycoprotein/CYP3A4 inhibitors.</p><p>Rifampicin:</p><p>Multiple co-administration of 5 mg linagliptin with rifampicin, a potent inductor of P-glycoprotein and CYP3A4, resulted in a 39.6% and 43.8% decreased linagliptin steady-state AUC and Cmax respectively, and about 30% decreased DPP-4 inhibition at trough. Thus full efficacy of linagliptin in combination with strong P-gp inducers might not be achieved, particularly if these are administered long-term. Co-administration with other potent inducers of P-glycoprotein and CYP3A4, such as carbamazepine, phenobarbital and phenytoin has not been studied.</p><p>Effects of linagliptin on other medicinal products</p><p>In clinical studies, as described below, linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cationic transporter (OCT).</p><p>Metformin:</p><p>Co-administration of multiple daily doses of 10 mg linagliptin with 850 mg metformin hydrochloride, an OCT substrate, had no relevant effect on the pharmacokinetics of metformin in healthy subjects.</p><p>Therefore, linagliptin is not an inhibitor of OCT-mediated transport.</p><p>Sulphonylureas:</p><p>Co-administration of multiple oral doses of 5 mg linagliptin and a single oral dose of 1.75 mg glibenclamide (glyburide) resulted in clinically not relevant reduction of 14% of both AUC and Cmax of glibenclamide. Because glibenclamide is primarily metabolised by CYP2C9, these data also support the conclusion that linagliptin is not a CYP2C9 inhibitor. Clinically meaningful interactions would not be expected with other sulphonylureas (e.g., glipizide, tolbutamide, and glimepiride) which, like glibenclamide, are primarily eliminated by CYP2C9.</p><p>Digoxin:</p><p>Co-administration of multiple daily doses of 5 mg linagliptin with multiple doses of 0.25 mg digoxin had no effect on the pharmacokinetics of digoxin in healthy subjects. Therefore, linagliptin is not an inhibitor of P-glycoprotein-mediated transport in vivo.</p><p>Warfarin:</p><p>Multiple daily doses of 5 mg linagliptin did not alter the pharmacokinetics of S(-) or R(+) warfarin, a CYP2C9 substrate, administered in a single dose.</p><p>Simvastatin:</p><p>Multiple daily doses of linagliptin had a minimal effect on the steady-state pharmacokinetics of simvastatin, a sensitive CYP3A4 substrate, in healthy subjects. Following administration of a supratherapeutic dose of 10 mg linagliptin concomitantly with 40 mg of simvastatin daily for 6 days, the plasma AUC of simvastatin was increased by 34%, and the plasma Cmax by 10%.</p><p>Oral contraceptives:</p><p>Co-administration with 5 mg linagliptin did not alter the steady-state pharmacokinetics of levonorgestrel or ethinylestradiol.</p><p>Metformin</p><p>Combination requiring precautions for use</p><p>Glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. If necessary, the dose of the anti-hyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation.</p><p>Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.</p><p><u>Organic cation transporters (OCT)</u></p><p>Metformin is a substrate of both transporters OCT1 and OCT2. Co-administration of metformin with</p><p>&bull; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.</p><p>&bull; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.</p><p>&bull; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.</p><p>&bull; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</p><p>Caution is therefore advised, especially in patients with renal impairment, when these drugs are coadministered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p><p><em>Concomitant use not recommended <u>Alcohol</u></em></p><p>Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of fasting, malnutrition or hepatic impairment.</p><p><em><u>Iodinated contrast agents</u></em></p><p>Zylinamet &nbsp;must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The use of linagliptin has not been studied in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>A limited amount of data suggests that the use of metformin in pregnant women is not associated with an increased risk of congenital malformations. Animal studies with metformin do not indicate harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>Non-clinical reproduction studies did not indicate an additive teratogenic effect attributed to the co- administration of linagliptin and metformin.</p><p>Zylinamet &nbsp;should not be used during pregnancy. If the patient plans to become pregnant, or if pregnancy occurs, treatment with Zylinamet &nbsp;should be discontinued and switched to insulin treatment as soon as possible in order to lower the risk of foetal malformations associated with abnormal blood glucose levels.</p><p><u>Breast-feeding</u></p><p>Studies in animals have shown excretion of both metformin and linagliptin into milk in lactating rats. Metformin is excreted in human milk in small amounts. It is not known whether linagliptin is excreted into human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zylinamet &nbsp;therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>The effect of Zylinamet &nbsp;on human fertility has not been studied. No adverse effects of linagliptin on fertility were observed in male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zylinamet &nbsp;has no or negligible influence on the ability to drive and use machines. However, patients should be alerted to the risk of hypoglycaemia when Zylinamet &nbsp;is used in combination with other anti-diabetic medicinal products known to cause hypoglycaemia (e.g. sulphonylureas).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of linagliptin 2.5 mg twice daily (or its bioequivalent of 5 mg once daily) in combination with metformin has been evaluated in over 6800 patients with type 2 diabetes mellitus. In placebo- controlled studies, more than 1800 patients were treated with the therapeutic dose of either 2.5 mg linagliptin twice daily (or its bioequivalent of 5 mg linagliptin once daily) in combination with metformin for &ge; 12/24 weeks.</p><p>In the pooled analysis of the seven placebo-controlled trials, the overall incidence of adverse events in patients treated with placebo and metformin was comparable to that seen with linagliptin 2.5 mg and metformin (54.3 and 49.0%). Discontinuation of therapy due to adverse events was comparable in patients who received placebo and metformin to patients treated with linagliptin and metformin (3.8% and 2.9%).</p><p>The most frequently reported adverse reaction for linagliptin plus metformin was diarrhoea (1.6%) with a comparable rate on metformin plus placebo (2.4%).</p><p>Hypoglycaemia may occur when Zylinamet &nbsp;is administered together with sulphonylurea (&ge; 1 case per 10 patients).</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions reported in all clinical trials with the linagliptin+metformin combination or the use of the monocomponents (linagliptin or metformin) in clinical trials or from post-marketing experience are shown below according to system organ class. Adverse reactions previously reported with one of the individual active substances may be potential adverse reactions with Zylinamet , even if not observed in clinical trials with this medicinal product.</p><p>The adverse reactions are listed by system organ class and absolute frequency. Frequencies are defined as very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), or very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</p><p>Table 2: Adverse reactions reported in patients who received linagliptin+metformin alone (as mono-components or in combination) or as add-on to other anti-diabetic therapies in clinical trial and from post-marketing experience</p><table border="1" cellspacing="0" cellpadding="0" style="width:569px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p>Adverse reaction</p></td><td style="vertical-align:top"><p><strong>Frequency</strong><strong> </strong><strong>of adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong><strong> </strong><strong>and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity</p><p>(e.g. bronchial hyperreactivity)</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism</strong><strong> </strong><strong>and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia <sup>1</sup></p></td><td style="vertical-align:top"><p>very common</p></td></tr><tr><td style="vertical-align:top"><p>Lactic acidosis <sup>&sect;</sup></p></td><td style="vertical-align:top"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Vitamin B12 deficiency <sup>&sect;</sup></p></td><td style="vertical-align:top"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong><strong> </strong><strong>system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Taste disturbance <sup>&sect;</sup></p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong><strong> </strong><strong>thoracic</strong><strong> </strong><strong>and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>rare<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Constipation <sup>2</sup></p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain <sup>&sect;</sup></p></td><td style="vertical-align:top"><p>very common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Liver function disorders <sup>2</sup></p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis <sup>&sect;</sup></p></td><td style="vertical-align:top"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin</strong><strong> </strong><strong>and</strong><strong> </strong><strong>subcutaneous</strong><strong> </strong><strong>tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Erythema<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Bullous pemphigoid</p></td><td style="vertical-align:top"><p>rare<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Amylase increased</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased*</p></td><td style="vertical-align:top"><p>common</p></td></tr></tbody></table><p>* Based on lipase elevations &gt;3xULN observed in clinical trials</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; #Based on <em>Linagliptin cardiovascular and renal safety study (CARMELINA)</em>, see also below</p><p>&sect; Adverse reactions reported in patients who received metformin as monotherapy and that were not observed in patients receiving Zylinamet . Refer to Summary of Product Characteristics for metformin for additional information</p><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reaction observed in combination of Zylinamet &nbsp;with sulphonylurea</p><p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reaction observed in combination of Zylinamet &nbsp;with insulin</p><p><u>Description of selected adverse reactions</u></p><p><em>Hypoglycaemia</em></p><p>In one study linagliptin was given as add-on to metformin plus sulphonylurea. When linagliptin and metformin were administered in combination with a sulphonylurea, hypoglycaemia was the most frequently reported adverse event (linagliptin plus metformin plus sulphonylurea 23.9% and 16.0% in placebo plus metformin plus sulphonylurea).</p><p>When linagliptin and metformin were administered in combination with insulin, hypoglycaemia was the most frequently reported adverse event, but occurred at comparable rate when placebo and metformin were combined with insulin (linagliptin plus metformin plus insulin 29.5% and 30.9% in the placebo plus metformin plus insulin group) with a low rate of severe (requiring assistance) episodes (1.5% and 0.9%).</p><p><em>Other adverse reactions</em></p><p>Gastrointestinal disorders such as, nausea, vomiting, diarrhoea and decreased appetite and abdominal pain occur most frequently during initiation of therapy with Zylinamet &nbsp;or metformin hydrochloride and resolve spontaneously in most cases. For prevention, it is recommended that Zylinamet &nbsp;be taken during or after meals. A slow increase in dose of metformin hydrochloride may also improve gastrointestinal tolerability.</p><p>Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia).</p><p><u>Linagliptin cardiovascular and renal safety study (CARMELINA)</u></p><p>The CARMELINA study evaluated the cardiovascular and renal safety of linagliptin versus placebo in patients with type 2 diabetes and with increased CV risk evidenced by a history of established macrovascular or renal disease (see section 5.1). The study included 3494 patients treated with linagliptin (5 mg) and 3485 patients treated with placebo. Both treatments were added to standard of care targeting regional standards for HbA1c and CV risk factors. The overall incidence of adverse events and serious adverse events in patients receiving linagliptin was similar to that in patients receiving placebo. Safety data from this study was in line with previous known safety profile of linagliptin.</p><p>In the treated population, severe hypoglycaemic events (requiring assistance) were reported in 3.0% of patients on linagliptin and in 3.1% on placebo. Among patients who were using sulfonylurea at baseline, the incidence of severe hypoglycaemia was 2.0% in linagliptin-treated patients and 1.7% in placebo treated patients. Among patients who were using insulin at baseline, the incidence of severe hypoglycaemia was 4.4% in linagliptin-treated patients and 4.9% in placebo treated patients.</p><p>In the overall study observation period adjudicated acute pancreatitis was reported in 0.3% of patients treated with linagliptin and in 0.1% of patients treated with placebo.</p><p>In the CARMELINA study, bullous pemphigoid was reported in 0.2% of patients treated with linagliptin and in no patient treated with placebo.</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Linagliptin</u></p><p>During controlled clinical trials in healthy subjects, single doses of up to 600 mg linagliptin (equivalent to 120 times the recommended dose) were not associated with a dose dependent increase in adverse events. There is no experience with doses above 600 mg in humans.</p><p><u>Metformin</u></p><p>Hypoglycaemia has not been seen with metformin hydrochloride doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose of metformin hydrochloride or concomitant risks may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin hydrochloride is haemodialysis.</p><p><u>Management</u></p><p>In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g. remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute clinical measures if required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD11</p><p>Zylinamet &nbsp;combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.</p><p>Linagliptin</p><p>Mechanism of action</p><p>Linagliptin is an inhibitor of the enzyme DPP-4 (Dipeptidyl peptidase 4) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucose- dependent insulinotropic polypeptide). These hormones are rapidly degraded by the enzyme DPP-4. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretins are secreted at a low basal level throughout the day and levels rise immediately after meal intake.</p><p>GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output. Linagliptin binds very effectively to DPP-4 in a reversible manner and thus leads to a sustained increase and a prolongation of active incretin levels. Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion thus resulting in an overall improvement in the glucose homeostasis. Linagliptin binds selectively to DPP-4 and exhibits a &gt; 10,000 fold selectivity versus DPP-8 or DPP-9 activity in vitro.</p><p><u>Metformin</u></p><p><em>Mechanism of action</em></p><p>Metformin hydrochloride is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.</p><p>Metformin hydrochloride may act via 3 mechanisms:</p><p>(1)&nbsp;&nbsp; reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis,</p><p>(2)&nbsp;&nbsp; in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation,</p><p>(3)&nbsp;&nbsp; and delay of intestinal glucose absorption.</p><p>Metformin hydrochloride stimulates intracellular glycogen synthesis by acting on glycogen synthase. Metformin hydrochloride increases the transport capacity of all types of membrane glucose transporters (GLUTs) known to date.</p><p>In humans, independently of its action on glycaemia, metformin hydrochloride has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long- term clinical studies: metformin hydrochloride reduces total cholesterol, LDL cholesterol and triglyceride levels.</p><p><em>Clinical efficacy and safety</em></p><p><em><u>Linagliptin as add-on to metformin therapy</u></em></p><p>The efficacy and safety of linagliptin in combination with metformin in patients with insufficient glycaemic control on metformin monotherapy was evaluated in a double-blind placebo-controlled study of 24 weeks duration. Linagliptin added to metformin provided significant improvements in HbA1c, (-0.64% change compared to placebo), from a mean baseline HbA1c of 8%. Linagliptin also showed significant improvements in fasting plasma glucose (FPG) by -21.1 mg/dl and 2-hour post- prandial glucose (PPG) by -67.1 mg/dl compared to placebo, as well as a greater portion of patients achieving a target HbA1c of &lt; 7.0% (28.3% on linagliptin <em>versus </em>11.4% on placebo). The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo. Body weight did not differ significantly between the groups.</p><p>In a 24-week placebo-controlled factorial study of initial therapy, linagliptin 2.5 mg twice daily in combination with metformin (500 mg or 1,000 mg twice daily) provided significant improvements in glycaemic parameters compared with either monotherapy as summarised in Table 3 (mean baseline HbA1c 8.65%).</p><p>Table 3: Glycaemic parameters at final visit (24-week study) for linagliptin and metformin, alone and in combination in patients with type 2 diabetes mellitus inadequately controlled on diet and exercise</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Linagliptin</strong></p><p><strong>5 mg Once Daily</strong>1</p></td><td style="vertical-align:top"><p><strong>Metformin HCl</strong></p><p><strong>500 mg Twice Daily</strong></p></td><td style="vertical-align:top"><p><strong>Linagliptin</strong></p><p><strong>2.5 mg</strong></p><p><strong>Twice Daily</strong>1 <strong>+ Metformin HCl 500 mg</strong></p><p><strong>Twice Daily</strong></p></td><td style="vertical-align:top"><p><strong>Metformin HCl</strong></p><p><strong>1,000 mg</strong></p><p><strong>Twice Daily</strong></p></td><td style="vertical-align:top"><p><strong>Linagliptin 2.5 mg</strong></p><p><strong>Twice Daily</strong>1 <strong>+ Metformin HCl 1,000 mg</strong></p><p><strong>Twice Daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>n = 65</p></td><td style="vertical-align:top"><p>n = 135</p></td><td style="vertical-align:top"><p>n = 141</p></td><td style="vertical-align:top"><p>n = 137</p></td><td style="vertical-align:top"><p>n = 138</p></td><td style="vertical-align:top"><p>n = 140</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>8.7</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-0.5</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-0.6</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-1.2</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-1.1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-1.6</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo</p><p>(adjusted mean) (95% CI)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>-0.6</p><p>(-0.9, -0.3)</p></td><td style="vertical-align:top"><p>-0.8</p><p>(-1.0, -0.5)</p></td><td style="vertical-align:top"><p>-1.3</p><p>(-1.6, -1.1)</p></td><td style="vertical-align:top"><p>-1.2</p><p>(-1.5, -0.9)</p></td><td style="vertical-align:top"><p>-1.7</p><p>(-2.0, -1.4)</p></td></tr><tr><td style="vertical-align:top"><p>Patients (n, %) achieving HbA1c</p><p>&lt;7%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7 (10.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14 (10.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>27 ( 19.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>42 (30.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>43 (31.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>76 (54.3)</p></td></tr><tr><td style="vertical-align:top"><p>Patients (%) receiving rescue treatment</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>29.2</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11.1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13.5</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.3</p></td></tr><tr><td style="vertical-align:top"><p>FPG (mg/dL)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>n = 61</p></td><td style="vertical-align:top"><p>n = 134</p></td><td style="vertical-align:top"><p>n = 136</p></td><td style="vertical-align:top"><p>n = 135</p></td><td style="vertical-align:top"><p>n = 132</p></td><td style="vertical-align:top"><p>n = 136</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>203</p></td><td style="vertical-align:top"><p>195</p></td><td style="vertical-align:top"><p>191</p></td><td style="vertical-align:top"><p>199</p></td><td style="vertical-align:top"><p>191</p></td><td style="vertical-align:top"><p>196</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted</p><p>mean)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-9</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-16</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-33</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-32</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-49</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean) (95% CI)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>-19</p><p>(-31, -6)</p></td><td style="vertical-align:top"><p>-26</p><p>(-38, -14)</p></td><td style="vertical-align:top"><p>-43</p><p>(-56, -31)</p></td><td style="vertical-align:top"><p>-42</p><p>(-55, -30)</p></td><td style="vertical-align:top"><p>-60</p><p>(-72, -47)</p></td></tr></tbody></table><p><sup>1 Total daily dose of linagliptin is equal to 5 mg</sup></p><p>Mean reductions from baseline in HbA1c were generally greater for patients with higher baseline HbA1c values. Effects on plasma lipids were generally neutral. The decrease in body weight with the combination of linagliptin and metformin was similar to that observed for metformin alone or placebo; there was no change in weight from baseline for patients on linagliptin alone. The incidence of hypoglycaemia was similar across treatment groups (placebo 1.4%, linagliptin 5 mg 0%, metformin 2.1%, and linagliptin 2.5 mg plus metformin twice daily 1.4%).</p><p>The efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in combination with metformin in patients with insufficient glycaemic control on metformin monotherapy was evaluated in a double-blind placebo-controlled study of 12 weeks duration. Linagliptin 5 mg once daily and 2.5 mg twice daily provided comparable (CI: -0.07; 0.19) significant HbA1c reductions of -0.80% (from baseline 7.98%), and -0.74% (from baseline 7.96%) compared to placebo. The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo. Body weight did not differ significantly between the groups.</p><p><u>Linagliptin as add-on to a combination of metformin and sulphonylurea therapy</u></p><p>A placebo-controlled study of 24 weeks in duration was conducted to evaluate the efficacy and safety of linagliptin 5 mg to placebo, in patients not sufficiently treated with a combination with metformin and a sulphonylurea. Linagliptin provided significant improvements in HbA1c (-0.62% change compared to placebo), from a mean baseline HbA1c of 8.14%. Linagliptin also showed significant improvements in patients achieving a target HbA1c of &lt; 7.0% (31.2% on linagliptin versus 9.2% on placebo), and also for fasting plasma glucose (FPG) with -12.7 mg/dl reduction compared to placebo. Body weight did not differ significantly between the groups.</p><p><u>Linagliptin as add on to a combination of metformin and empagliflozin therapy</u></p><p>In patients inadequately controlled with metformin and empagliflozin (10 mg (n=247) or 25 mg (n=217)), 24-weeks treatment with add-on therapy of linagliptin 5 mg provided adjusted mean HbA1c reductions from baseline by -0.53% (significant difference to add-on placebo -0.32% (95% CI -0.52,</p><p>-0.13) and -0.58% (significant difference to add-on placebo -0.47% (95% CI -0.66; -0.28), respectively. A statistically significant greater proportion of patients with a baseline HbA1c &ge;7.0% and treated with linagliptin 5 mg achieved a target HbA1c of &lt;7% compared to placebo.</p><p><u>Linagliptin in combination with metformin and insulin</u></p><p>A 24-week placebo-controlled study was conducted to evaluate the efficacy and safety of linagliptin (5 mg once daily) added to insulin with or without metformin. 83% of patients were taking metformin in combination with insulin in this trial. Linagliptin in combination with metformin plus insulin provided significant improvements in HbA1c in this subgroup with -0.68% (CI: -0.78; -0,57) adjusted mean change from baseline (mean baseline HbA1c 8.28%) compared to placebo in combination with metformin plus insulin. There was no meaningful change from baseline in body weight in either group.</p><p><em><u>Linagliptin 24 month data, as add-on to metformin in comparison with glimepiride</u></em></p><p>In a study comparing the efficacy and safety of the addition of linagliptin 5 mg or glimepiride (mean dose 3 mg) in patients with inadequate glycaemic control on metformin monotherapy, mean reductions in HbA1c were -0.16% with linagliptin (mean baseline HbA1c 7.69%) and -0.36% with glimepiride (mean baseline HbA1c 7.69%.) with a mean treatment difference of 0.20% (97.5% CI: 0.09, 0.299).</p><p>The incidence of hypoglycaemia in the linagliptin group (7.5%) was significantly lower than that in the glimepiride group (36.1%). Patients treated with linagliptin exhibited a significant mean decrease from baseline in body weight compared to a significant weight gain in patients administered glimepiride (-1.39 <em>versus </em>+1.29 kg).</p><p><em><u>Linagliptin as add-on therapy in elderly (age &ge; 70 years) with type 2 diabetes</u></em></p><p>The efficacy and safety of linagliptin in elderly (age &ge; 70 years) with type 2 diabetes was evaluated in a double-blind study of 24 weeks duration. Patients received metformin and/or sulphonylurea and/or insulin as background therapy. Doses of background anti-diabetic therapy were kept stable during the first 12 weeks, after which adjustments were permitted. Linagliptin provided significant improvements in HbA1c (-0.64% change compared to placebo after 24 weeks), from a mean baseline HbA1c of 7.8%. Linagliptin also showed significant improvements in fasting plasma glucose (FPG) compared to placebo. Body weight did not differ significantly between the groups.</p><p>In a pooled analysis of elderly (age &ge; 70 years) patients with type 2 diabetes (n=183) who were taking both metformin and basal insulin as background therapy, linagliptin in combination with metformin plus insulin provided significant improvements in HbA1c parameters with -0.81% (CI: -1.01; -0.61) adjusted mean change from baseline (mean baseline HbA1c 8.13%) compared to placebo in combination with metformin plus insulin.</p><p><em><u>Linagliptin cardiovascular and renal safety study (CARMELINA)</u></em></p><p>CARMELINA was a randomized study in 6979 patients with type 2 diabetes with increased CV risk evidenced by a history of established macrovascular or renal disease who were treated with linagliptin 5 mg (3494) or placebo (3485) added to standard of care targeting regional standards for HbA1c, CV risk factors and renal disease. The study population included 1211 (17.4%) patients &ge; 75 years of age and 4348 (62.3%) patients with renal impairment. Approximately 19% of the population had eGFR</p><p>&ge;45 to &lt;60 mL/min/1.73 m<sup>2</sup>, 28% of the population had eGFR &ge;30 to &lt;45 mL/min/1.73 m<sup>2</sup>) and 15% had eGFR &lt; 30 mL/min/1.73 m<sup>2</sup>. The mean HbA1c at baseline was 8.0%.</p><p>The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint which was a composite of the first occurrence of cardiovascular death or a non-fatal myocardial infarction (MI) or a non-fatal stroke (3P-MACE). The renal composite endpoint was defined as renal death or sustained end stage renal disease or sustained decrease of 40% or more in eGFR.</p><p>After a median follow up of 2.2 years, linagliptin, when added to standard of care, did not increase the risk of major adverse cardiovascular events or renal outcome events. There was no increased risk in hospitalization for heart failure which was an additional adjudicated endpoint observed compared to standard of care without linagliptin in patients with type 2 diabetes (table 4).</p><p>Table 4: Cardiovascular and renal outcomes by treatment group in the CARMELINA study</p><table border="1" cellspacing="0" cellpadding="0" style="width:672px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Linagliptin 5mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of Subjects (%)</p></td><td style="vertical-align:top"><p>Incidence</p><p>Rate per 1000 PY*</p></td><td style="vertical-align:top"><p>Number of Subjects (%)</p></td><td style="vertical-align:top"><p>Incidence</p><p>Rate per 1000 PY*</p></td><td style="vertical-align:top"><p>(95% CI)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>3494</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3485</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Primary CV composite (Cardiovascular death, non-fatal MI,</p><p>non-fatal stroke)</p></td><td style="vertical-align:top"><p>434 (12.4)</p></td><td style="vertical-align:top"><p>57.7</p></td><td style="vertical-align:top"><p>420 (12.1)</p></td><td style="vertical-align:top"><p>56.3</p></td><td style="vertical-align:top"><p>1.02 (0.89,</p><p>1.17)**</p></td></tr><tr><td style="vertical-align:top"><p>Secondary renal composite (renal death, ESRD, 40% sustained decrease</p><p>in eGFR)</p></td><td style="vertical-align:top"><p>327 (9.4)</p></td><td style="vertical-align:top"><p>48.9</p></td><td style="vertical-align:top"><p>306 (8.8)</p></td><td style="vertical-align:top"><p>46.6</p></td><td style="vertical-align:top"><p>1.04 (0.89,</p><p>1.22)</p></td></tr><tr><td style="vertical-align:top"><p>All-cause mortality</p></td><td style="vertical-align:top"><p>367 (10.5)</p></td><td style="vertical-align:top"><p>46.9</p></td><td style="vertical-align:top"><p>373 (10.7)</p></td><td style="vertical-align:top"><p>48.0</p></td><td style="vertical-align:top"><p>0.98 (0.84,</p><p>1.13)</p></td></tr><tr><td style="vertical-align:top"><p>CV death</p></td><td style="vertical-align:top"><p>255 (7.3)</p></td><td style="vertical-align:top"><p>32.6</p></td><td style="vertical-align:top"><p>264 (7.6)</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>0.96 (0.81,</p><p>1.14)</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for heart failure</p></td><td style="vertical-align:top"><p>209 (6.0)</p></td><td style="vertical-align:top"><p>27.7</p></td><td style="vertical-align:top"><p>226 (6.5)</p></td><td style="vertical-align:top"><p>30.4</p></td><td style="vertical-align:top"><p>0.90 (0.74,</p><p>1.08)</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp; &nbsp;PY=patient years</p><p>** Test on non-inferiority to demonstrate that the upper bound of the 95% CI for the hazard ratio is less than 1.3</p><p>In analyses for albuminuria progression (change from normoalbuminuria to micro- or macroalbuminuria, or from microalbuminuria to macroalbuminuria) the estimated hazard ratio was 0.86 (95% CI 0.78, 0.95) for linagliptin versus placebo.</p><p><em><u>Linagliptin cardiovascular safety study (CAROLINA)</u></em></p><p>CAROLINA was a randomized study in 6033 patients with early type 2 diabetes and increased CV risk or established complications who were treated with linagliptin 5 mg (3023) or glimepiride 1-4mg (3010) added to standard of care (including background therapy with metformin in 83% of patients) targeting regional standards for HbA1c and CV risk factors. The mean age for study population was 64 years and included 2030 (34%) patients &ge; 70 years of age. The study population included</p><p>2089 (35%) patients with cardiovascular disease and 1130 (19%) patients with renal impairment with an eGFR &lt; 60ml/min/1.73m<sup>2</sup> at baseline. The mean HbA1c at baseline was 7.15%</p><p>The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint which was a composite of the first occurrence of cardiovascular death or a non-fatal myocardial infarction (MI) or a non-fatal stroke (3P-MACE).</p><p>After a median follow up of 6.25 years, linagliptin, when added to standard of care, did not increase the risk of major adverse cardiovascular events (table 5) as compared to glimepiride. Results were consistent for patients treated with or without metformin.</p><p>Table 5: Major adverse cardiovascular events (MACE) and mortality by treatment group in the CAROLINA study</p><table border="1" cellspacing="0" cellpadding="0" style="width:593px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Linagliptin 5mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Glimepiride</strong><strong> </strong><strong>(1-4mg)</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of</p><p>Subjects (%)</p></td><td style="vertical-align:top"><p>Incidence</p><p>Rate per 1000 PY*</p></td><td style="vertical-align:top"><p>Number of Subjects (%)</p></td><td style="vertical-align:top"><p>Incidence</p><p>Rate per 1000 PY*</p></td><td style="vertical-align:top"><p>(95% CI)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td colspan="2" style="vertical-align:top"><p>3023</p></td><td colspan="2" style="vertical-align:top"><p>3010</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Primary CV composite (Cardiovascular death, non-fatal MI,</p><p>non-fatal stroke)</p></td><td style="vertical-align:top"><p>356 (11.8)</p></td><td style="vertical-align:top"><p>20.7</p></td><td style="vertical-align:top"><p>362 (12.0)</p></td><td style="vertical-align:top"><p>21.2</p></td><td style="vertical-align:top"><p>0.98 (0.84,</p><p>1.14)**</p></td></tr><tr><td style="vertical-align:top"><p>All-cause mortality</p></td><td style="vertical-align:top"><p>308 (10.2)</p></td><td style="vertical-align:top"><p>16.8</p></td><td style="vertical-align:top"><p>336 (11.2)</p></td><td style="vertical-align:top"><p>18.4</p></td><td style="vertical-align:top"><p>0.91 (0.78,1.06)</p></td></tr><tr><td style="vertical-align:top"><p>CV death</p></td><td style="vertical-align:top"><p>169 (5.6)</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>168 (5.6)</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>1.00 (0.81, 1.24)</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for heart failure (HHF)</p></td><td style="vertical-align:top"><p>112 (3.7)</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>92 (3.1)</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>1.21 (0.92, 1.59)</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp; &nbsp;PY=patient years</p><p>** Test on non-inferiority to demonstrate that the upper bound of the 95% CI for the hazard ratio is less than 1.3</p><p>For the entire treatment period (median time on treatment 5.9 years) the rate of patients with moderate or severe hypoglycaemia was 6.5% on linagliptin versus 30.9% on glimepiride, severe hypoglycaemia occurred in 0.3% of patients on linagliptin versus 2.2% on glimepiride.</p><p><em><u>Metformin</u></em></p><p>The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:</p><p>&bull; a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) <em>versus </em>diet alone (43.3 events/1,000 patient-years), p=0.0023, and <em>versus </em>the combined sulphonylurea and insulin monotherapy groups</p><p>(40.1 events/1,000 patient-years), p=0.0034,</p><p>&bull; a significant reduction of the absolute risk of any diabetes-related mortality: metformin</p><p>7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017,</p><p>&bull; a significant reduction of the absolute risk of overall mortality: metformin</p><p>13.5 events/1,000 patient-years <em>versus</em><em> </em>diet alone 20.6 events/1,000 patient-years, (p=0.011), and <em>versus </em>the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient- years (p=0.021),</p><p>&bull;&nbsp;a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01).</p><p><u>Paediatric</u><u> </u><u>population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of the studies with Zylinamet &nbsp;in all subsets of the paediatric population in type 2 diabetes (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bioequivalence studies in healthy subjects demonstrated that the Zylinamet &nbsp;(linagliptin/metformin hydrochloride) combination tablets are bioequivalent to co-administration of linagliptin and metformin hydrochloride as individual tablets.</p><p>Administration of Zylinamet &nbsp;2.5/1,000 mg with food resulted in no change in overall exposure of linagliptin. With metformin there was no change in AUC, however mean peak serum concentration of metformin was decreased by 18% when administered with food. A delayed time to peak serum concentrations by 2 hours was observed for metformin under fed conditions. These changes are not likely to be clinically meaningful.</p><p>The following statements reflect the pharmacokinetic properties of the individual active substances of Zylinamet .</p><p><u>Linagliptin</u></p><p>The pharmacokinetics of linagliptin has been extensively characterised in healthy subjects and patients with type 2 diabetes. After oral administration of a 5 mg dose to healthy volunteers or patients, linagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1.5 hours post-dose.</p><p>Plasma concentrations of linagliptin decline in a triphasic manner with a long terminal half-life (terminal half-life for linagliptin more than 100 hours), that is mostly related to the saturable, tight binding of linagliptin to DPP-4 and does not contribute to the accumulation of the active substance. The effective half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of 5 mg linagliptin, is approximately 12 hours. After once daily dosing of 5 mg linagliptin, steady-state plasma concentrations are reached by the third dose. Plasma AUC of linagliptin increased approximately 33% following 5 mg doses at steady-state compared to the first dose. The intra-subject and inter-subject coefficients of variation for linagliptin AUC were small (12.6% and 28.5%, respectively). Due to the concentration dependent binding of linagliptin to DPP- IV, the pharmacokinetics of linagliptin based on total exposure is not linear; indeed total plasma AUC of linagliptin increased in a less than dose-proportional manner, while unbound AUC increases in a roughly dose-proportional manner. The pharmacokinetics of linagliptin was generally similar in healthy subjects and in patients with type 2 diabetes.</p><p><em>Absorption</em></p><p>The absolute bioavailability of linagliptin is approximately 30%. Co-administration of a high-fat meal with linagliptin prolonged the time to reach Cmax by 2 hours and lowered Cmax by 15%, but no influence on AUC 0-72h was observed. No clinically relevant effect of Cmax and Tmax changes is expected; therefore linagliptin may be administered with or without food.</p><p><em>Distribution</em></p><p>As a result of tissue binding, the mean apparent volume of distribution at steady-state following a single 5 mg intravenous dose of linagliptin to healthy subjects is approximately 1110 litres, indicating that linagliptin extensively distributes to the tissues. Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/l to 75-89% at &ge; 30 nmol/l, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin At high concentrations, where DPP-4 is fully saturated, 70-80% of linagliptin was bound to other plasma proteins than DPP-4, hence 20-30% were unbound in plasma.</p><p><em>Biotransformation</em></p><p>Following a [<sup>14</sup>C] linagliptin oral 10 mg dose, approximately 5% of the radioactivity was excreted in urine. Metabolism plays a subordinate role in the elimination of linagliptin. One main metabolite with a relative exposure of 13.3% of linagliptin at steady-state was detected which was found to be pharmacologically inactive, and thus does not contribute to the plasma DPP-4 inhibitory activity of linagliptin.</p><p><em>Elimination</em></p><p>Following administration of an oral [<sup>14</sup>C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing. Renal clearance at steady-state was approximately 70 ml/min.</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>Under steady-state conditions, linagliptin exposure in patients with mild renal impairment was comparable to healthy subjects. In moderate renal impairment, a moderate increase in exposure of about 1.7 fold was observed compared with control. Exposure in T2DM patients with severe RI was increased by about 1.4 fold compared to T2DM patients with normal renal function. Steady-state predictions for AUC of linagliptin in patients with ESRD indicated comparable exposure to that of patients with moderate or severe renal impairment. In addition, linagliptin is not expected to be eliminated to a therapeutically significant degree by hemodialysis or peritoneal dialysis. No dose adjustment of linagliptin is recommended in patients with renal impairment; therefore, linagliptin may be continued as a single entity tablet at the same total daily dose of 5 mg if Zylinamet &nbsp;is discontinued due to evidence of renal impairment.</p><p><em>Hepatic</em><em> </em><em>impairment</em></p><p>In patients with mild moderate and severe hepatic impairment (according to the Child-Pugh classification),&nbsp;mean AUC and Cmax of linagliptin were similar to healthy matched controls following administration of multiple 5 mg doses of linagliptin.</p><p><em>Body Mass Index (BMI)</em></p><p>Body mass index had no clinically relevant effect on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. The clinical trials before marketing authorization have been performed up to a BMI equal to 40 kg/m<sup>2</sup>.</p><p><em>Gender</em></p><p>Gender had no clinically relevant effect on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data<em>.</em></p><p><em>Elderly</em></p><p>Age did not have a clinically relevant impact on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. Older subjects (65 to 80 years, oldest patient was 78 years) had comparable plasma concentrations of linagliptin compared to younger subjects. Linagliptin trough concentrations were also measured in elderly (age &ge; 70 years) with type 2 diabetes in a phase III study of 24 weeks duration. Linagliptin concentrations in this study were within the range of values previously observed in younger type 2 diabetes patients.</p><p><em>Paediatric</em><em> </em><em>population</em></p><p>A paediatric Phase 2 study examined the pharmacokinetics and pharmacodynamics of 1 mg and 5 mg linagliptin in children and adolescents &ge;10 to &lt;18 years of age with type 2 diabetes mellitus. The observed pharmacokinetic and pharmacodynamic responses were consistent with those found in adult subjects. Linagliptin 5 mg showed superiority over 1 mg with regard to trough DPP-4 inhibition (72% vs 32%, p=0.0050) and a numerically larger reduction with regard to adjusted mean change from baseline in HbA1c (-0.63% vs -0.48%, n.s.). Due to the limited nature of the data set the results should be interpreted cautiously<em>.</em></p><p><em>Race</em></p><p>Race had no obvious effect on the plasma concentrations of linagliptin based on a composite analysis of available pharmacokinetic data, including patients of Caucasian, Hispanic, African, and Asian origin<em>. </em>In addition the pharmacokinetic characteristics of linagliptin were found to be similar in dedicated phase I studies in Japanese, Chinese and Caucasian healthy subjects and African American type 2 diabetes patients.</p><p><u>Metformin</u></p><p>&nbsp;<em>Absorption</em></p><p>After an oral dose of metformin, Tmax is reached in 2.5 hours. Absolute bioavailability of a 500 mg or 850 mg metformin hydrochloride tablet is approximately 50-60% in healthy subjects. After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.</p><p>After oral administration, metformin hydrochloride absorption is saturable and incomplete. It is assumed that the pharmacokinetics of metformin hydrochloride absorption are non-linear.</p><p>At the recommended metformin hydrochloride doses and dosing schedules, steady-state plasma concentrations are reached within 24 to 48 hours and are generally less than 1 microgram/ml. In controlled&nbsp;clinical&nbsp;trials,&nbsp;maximum&nbsp;metformin hydrochloride plasma levels (Cmax) did not exceed 5 microgram/ml, even at maximum doses.</p><p>Food decreases the extent and slightly delays the absorption of metformin hydrochloride. Following administration of a dose of 850 mg, a 40% lower plasma peak concentration, a 25% decrease in AUC (area under the curve) and a 35 minute prolongation of the time to peak plasma concentration were observed. The clinical relevance of these decreases is unknown.</p><p><em>Distribution</em></p><p>Plasma protein binding is negligible. Metformin hydrochloride partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution (Vd) ranged between 63-276 l.</p><p><em>Biotransformation</em></p><p>Metformin hydrochloride is excreted unchanged in the urine. No metabolites have been identified in humans.</p><p><em>Elimination</em></p><p>Renal clearance of metformin hydrochloride is &gt; 400 ml/min, indicating that metformin hydrochloride is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.</p><p>When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin hydrochloride in plasma.</p><p><em>Paediatric</em><em> </em><em>population</em></p><p>Single dose study: after single doses of metformin hydrochloride 500 mg, paediatric patients have shown a similar pharmacokinetic profile to that observed in healthy adults.</p><p>Multiple-dose study: data are restricted to one study. After repeated doses of 500 mg twice daily for 7 days&nbsp;in&nbsp;paediatric&nbsp;patients the peak plasma concentration (Cmax) and systemic exposure (AUC0-t) were reduced by approximately 33% and 40%, respectively compared to diabetic adults who received repeated doses of 500 mg twice daily for 14 days. As the dose is individually titrated based on glycaemic control, this is of limited clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Linagliptin plus metformin</u></p><p>General toxicity studies in rats for up to 13 weeks were performed with the co-administration of linagliptin and metformin. The only observed interaction between linagliptin and metformin was a reduction of body weight gain. No other additive toxicity caused by the combination of linagliptin and metformin was observed at AUC exposure levels up to 2 and 23 times human exposure, respectively.</p><p>An embryofetal development study in pregnant rats did not indicate a teratogenic effect attributed to the co-administration of linagliptin and metformin at AUC exposure levels up to 4 and 30 times human exposure, respectively.</p><p><u>Linagliptin</u></p><p>Liver, kidneys and gastrointestinal tract are the principal target organs of toxicity in mice and rats at repeat doses of linagliptin of more than 300 times the human exposure.</p><p>In rats, effects on reproductive organs, thyroid and the lymphoid organs were seen at more than 1500 times human exposure. Strong pseudo-allergic reactions were observed in dogs at medium doses, secondarily causing cardiovascular changes, which were considered dog-specific. Liver, kidneys, stomach, reproductive organs, thymus, spleen, and lymph nodes were target organs of toxicity in Cynomolgus monkeys at more than 450 times human exposure. At more than 100 times human exposure, irritation of the stomach was the major finding in these monkeys.</p><p>Linagliptin and its main metabolite did not show a genotoxic potential.</p><p>Oral 2 year carcinogenicity studies in rats and mice revealed no evidence of carcinogenicity in rats or male mice. A significantly higher incidence of malignant lymphomas only in female mice at the highest dose (&gt; 200 times human exposure) is not considered relevant for humans (explanation: non- treatment related but due to highly variable background incidence). Based on these studies there is no concern for carcinogenicity in humans.</p><p>The NOAEL for fertility, early embryonic development and teratogenicity in rats was set at</p><p>&gt; 900 times the human exposure. The NOAEL for maternal-, embryo-fetal-, and offspring toxicity in rats was 49 times human exposure. No teratogenic effects were observed in rabbits at &gt; 1,000 times human exposure. A NOAEL of 78 times human exposure was derived for embryo-fetal toxicity in rabbits, and for maternal toxicity the NOAEL was 2.1 times human exposure. Therefore, it is considered unlikely that linagliptin affects reproduction at therapeutic exposures in humans.</p><p><u>Metformin</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Zylinamet 2.5 mg/500 mg film-coated tablets</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:276px"><tbody><tr><td><p><strong>S. No.</strong></p></td><td><p><strong>Ingredients</strong></p></td></tr><tr><td><p>1.</p></td><td><p>Maize starch</p></td></tr><tr><td><p>2.</p></td><td><p>Co Povidone VA 64</p></td></tr><tr><td><p>3.</p></td><td><p>Colloidal silicon dioxide</p></td></tr><tr><td><p>4.</p></td><td><p>Magnesium Stearate</p></td></tr><tr><td><p>5.</p></td><td><p>Opadry II Yellow (03H520063)</p></td></tr></tbody></table><p><strong><u>Zylinamet </u></strong><strong><u>2.5</u></strong><strong><u> </u></strong><strong><u>mg/850 mg film-coated tablets</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:270px"><tbody><tr><td style="vertical-align:top"><p><strong>S. No.</strong></p></td><td style="vertical-align:top"><p><strong>Ingredients</strong></p></td></tr><tr><td><p>1.</p></td><td><p>Maize starch</p></td></tr><tr><td><p>2.</p></td><td><p>Co Povidone VA 64</p></td></tr><tr><td><p>3.</p></td><td><p>Colloidal silicon dioxide</p></td></tr><tr><td><p>4.</p></td><td><p>Magnesium Stearate</p></td></tr><tr><td><p>5.</p></td><td><p>Opadry II (03H570011) Beige</p></td></tr></tbody></table><p><strong><u>Zylinamet </u></strong><strong><u>2.5</u></strong><strong><u> </u></strong><strong><u>mg/1000 mg film-coated tablets</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:270px"><tbody><tr><td style="vertical-align:top"><p><strong>S. No.</strong></p></td><td style="vertical-align:top"><p><strong>Ingredients</strong></p></td></tr><tr><td><p>1.</p></td><td><p>Maize starch</p></td></tr><tr><td><p>2.</p></td><td><p>Co Povidone VA 64</p></td></tr><tr><td><p>3.</p></td><td><p>Colloidal silicon dioxide</p></td></tr><tr><td><p>4.</p></td><td><p>Magnesium Stearate</p></td></tr><tr><td><p>5.</p></td><td><p>Opadry II (03H540023) Pink</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Store below 30 &deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>2.5/500 mg: </strong>Zylinamet 2.5/500 mg is available in blister packs containing 7 tablets and each box contains 8 blisters (56 Tablets).</p><p><strong>2.5/850 mg: </strong>Zylinamet 2.5/850 mg is available in blister packs containing 7 tablets and each box contains 8 blisters (56 Tablets).</p><p><strong>2.5/1000 mg: </strong>Zylinamet 2.5/1000 mg is available in blister packs containing 7 tablets and each box contains 8 blisters (56 Tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alrai Pharmaceutical Industries Co. (L.L.C.)
Al Wadi, Building No. 2684, Additional No. 6236 
Unit No. 1, Jeddah 22518 Almu'tasem Bellah Al Fatemy Street 
P.O.Box : 9224, Postal code 21413. Kingdom of Saudi Arabia 
Tel: +966 12 2888949 
E-mail: info@alraipharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>